299 related articles for article (PubMed ID: 27573544)
21. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW
Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
[TBL] [Abstract][Full Text] [Related]
23. The impact of binding site waters on the activity/selectivity trade-off of Janus kinase 2 (JAK2) inhibitors.
Egyed A; Bajusz D; Keserű GM
Bioorg Med Chem; 2019 Apr; 27(8):1497-1508. PubMed ID: 30833158
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a Selective Aurora A Kinase Inhibitor by Virtual Screening.
Kilchmann F; Marcaida MJ; Kotak S; Schick T; Boss SD; Awale M; Gönczy P; Reymond JL
J Med Chem; 2016 Aug; 59(15):7188-211. PubMed ID: 27391133
[TBL] [Abstract][Full Text] [Related]
25. Systematic Computational Design and Identification of Low Picomolar Inhibitors of Aurora Kinase A.
Park H; Jung HY; Mah S; Hong S
J Chem Inf Model; 2018 Mar; 58(3):700-709. PubMed ID: 29401391
[TBL] [Abstract][Full Text] [Related]
26. The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
Wang HL; Cee VJ; Chavez F; Lanman BA; Reed AB; Wu B; Guerrero N; Lipford JR; Sastri C; Winston J; Andrews KL; Huang X; Lee MR; Mohr C; Xu Y; Zhou Y; Tasker AS
Bioorg Med Chem Lett; 2015 Feb; 25(4):834-40. PubMed ID: 25597005
[TBL] [Abstract][Full Text] [Related]
27. Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity.
Cai J; Li L; Hong KH; Wu X; Chen J; Wang P; Cao M; Zong X; Ji M
Bioorg Med Chem; 2014 Nov; 22(21):5813-23. PubMed ID: 25270403
[TBL] [Abstract][Full Text] [Related]
28. Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.
Shiao HY; Coumar MS; Chang CW; Ke YY; Chi YH; Chu CY; Sun HY; Chen CH; Lin WH; Fung KS; Kuo PC; Huang CT; Chang KY; Lu CT; Hsu JT; Chen CT; Jiaang WT; Chao YS; Hsieh HP
J Med Chem; 2013 Jul; 56(13):5247-60. PubMed ID: 23808327
[TBL] [Abstract][Full Text] [Related]
29. Indazole Derivatives: Promising Anti-tumor Agents.
Wan Y; He S; Li W; Tang Z
Anticancer Agents Med Chem; 2018; 18(9):1228-1234. PubMed ID: 29745343
[TBL] [Abstract][Full Text] [Related]
30. Discovery of Novel N-Substituted Prolinamido Indazoles as Potent Rho Kinase Inhibitors and Vasorelaxation Agents.
Yao Y; Li R; Liu X; Yang F; Yang Y; Li X; Shi X; Yuan T; Fang L; Du G; Jiao X; Xie P
Molecules; 2017 Oct; 22(10):. PubMed ID: 29048389
[TBL] [Abstract][Full Text] [Related]
31. N
Aboelfotouh HG; Abdallah M; Khalifa H; Aboushady Y; Abadi AH; Engel M; Abdel-Halim M
Arch Pharm (Weinheim); 2024 Jun; 357(6):e2400020. PubMed ID: 38478964
[TBL] [Abstract][Full Text] [Related]
32. Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer.
Sankhe K; Prabhu A; Khan T
Chem Biol Drug Des; 2021 Jul; 98(1):73-93. PubMed ID: 33934503
[TBL] [Abstract][Full Text] [Related]
33. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors.
Zheng Y; Zheng M; Ling X; Liu Y; Xue Y; An L; Gu N; Ji M
Bioorg Med Chem Lett; 2013 Jun; 23(12):3523-30. PubMed ID: 23664099
[TBL] [Abstract][Full Text] [Related]
35. Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors.
Chen T; Sorna V; Choi S; Call L; Bearss J; Carpenter K; Warner SL; Sharma S; Bearss DJ; Vankayalapati H
Bioorg Med Chem Lett; 2017 Dec; 27(24):5473-5480. PubMed ID: 29150397
[TBL] [Abstract][Full Text] [Related]
36. Discovery of 7-aryl-substituted (1,5-naphthyridin-4-yl)ureas as aurora kinase inhibitors.
Defaux J; Antoine M; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
ChemMedChem; 2014 Jan; 9(1):217-32. PubMed ID: 24273104
[TBL] [Abstract][Full Text] [Related]
37. Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.
Jung Y; Shin SY; Yong Y; Jung H; Ahn S; Lee YH; Lim Y
Chem Biol Drug Des; 2015 May; 85(5):574-85. PubMed ID: 25298094
[TBL] [Abstract][Full Text] [Related]
38. Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells.
Furqan M; Huma Z; Ashfaq Z; Nasir A; Ullah R; Bilal A; Iqbal M; Khalid MH; Hussain I; Faisal A
Cell Cycle; 2019 Sep; 18(18):2281-2292. PubMed ID: 31318643
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.
Bo YX; Xiang R; Xu Y; Hao SY; Wang XR; Chen SW
Bioorg Med Chem; 2020 Mar; 28(5):115351. PubMed ID: 32035750
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
